

IFW



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Michael KARAS <i>et al.</i>)	Group Art No. 1646
)	
Serial No.: 10/790,768)	Examiner: TBA
)	
Filed: March 3, 2004)	Docket No: 002877.00028

For: INTRACELLULAR DELIVERY OF SMALL MOLECULES,
PROTEINS, AND NUCLEIC ACIDS

INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
220 20th Street South
Customer Window, Mail Stop Amendment
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir:


A Form PTO-1449 is attached, identifying information for the Examiner's consideration.

Copies of the listed documents are enclosed.


We believe no fee is due in connection with this filing. If a fee is due, please charge our
Deposit Account No. 19-0733.

Respectfully submitted,
BANNER & WITCOFF, LTD.

Dated: August 13, 2004

By: 
Lisa M. Hemmendinger
Reg. No. 42,653

1001 G Street, N.W.
Eleventh Floor
Washington, D.C. 20001-4597
(202) 824-3000



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/790,768
Filing Date	March 3, 2004
First Named Inventor	Michael KARAS
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	002877.00028

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CONEJERO et al., "Glutamate and Antimitotic Agents Induce Differentiation, p53 Activation, and Apoptosis in Rodent Neostriatal Cell Lines Immortalized with the tsA58 Allele of SV40 Large T Antigen," 1999, <i>Experimental Neurology</i> , Vol. 158, pp. 109-120.	
		DERER et al., "Direct Protein Transfer to Terminally Differentiated Muscle Cells," 1999, <i>J. Mol. Med.</i> , Vol. 77, pp. 609-613.	
		GUENAL et al., "Bcl-2 and Hsp27 Act at Different Levels to Suppress Programmed Cell Death," 1997, <i>Oncogene</i> , Vol. 15, pp. 347-360.	
		KIM et al., "Survival of Conditionally Immortalized Hepatocytes in the Spleen of Syngeneic Rats," 2001, <i>Journal of Gastroenterology and Hepatology</i> , Vol. 16, pp. 52-60.	
		MI et al., "Characterization of a Class of Cationic Peptides Able to Facilitate Efficient Protein Transduction in Vitro and in Vivo," October 2000, <i>Molecular Therapy</i> , Vol. 2, No. 4, pp. 339-347.	
		MORRIS et al., "A Peptide Carrier for the Delivery of Biologically Active Proteins into Mammalian Cells," December 2001, <i>Nature Biotechnology</i> , Vol. 19, pp. 1173-1176.	
		SCHWARTZ & Zhang, "Peptide-Mediated Cellular Delivery," 2000, <i>Current Opinion in Molecular Therapeutics</i> , Vol. 2(2) (5 pages).	
		URQUIDI et al., "Role of Telomerase in Cell Senescence and Oncogenesis," 2000, <i>Ann. Rev. Med.</i> , Vol. 51, pp. 65-79.	
		VOCERO-AKBANI et al., "Protein Transduction: Delivery of Tat-GTPase Fusion Proteins into Mammalian Cells," <i>Regulators and Effectors of Small GTPases</i> , Vol. 332, pp. 36-49, 2001.	
		WADIA & Dowdy, "Protein Transduction Technology," 2002, <i>Curr. Opin. Biotechnology</i> , Vol. 13, pp. 52-56.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.